Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIQVIA Holdings Inc

IQVIA Holdings Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
278.24 USD 6.41 ( 2.36%)
Last update at 2026-11-09T17:54:00Z
VOLUME
349332
Market Cap
41062.50M
P/E
37.82

Momentum Score

…

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
270.00
Low
278.45
High
52 Week Price Range
167.42
Low
241.86
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

IQVIA Holdings Inc provides analytics, technology and contract research services to the global life‑sciences industry. Long‑term growth could be supported by rising pharma and biotech R&D outsourcing, greater demand for real‑world evidence, and monetization of large proprietary data assets, and investors may find the company attractive for its scale and integrated service mix.
Major risks include sensitivity to pharma R&D cycles and clinical‑trial volumes, intense competition and pricing pressure, integration and execution risk from acquisitions, and regulatory or data‑privacy developments that could constrain access to or use of data.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
271.83
Dividend Yield
-
Revenue TTM
14855.00M
Revenue Per Share
80.44
Gross Profit TTM
5028.00M
Debt / Equity
2.26
ROE
20.01%
Net Debt
11795.00M
ROCE
9.10%
Diluted EPS TTM
5.95

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 1363.00M 1128.00M 373.00M 352.00M 328.00M
Minority interest 0.00M -5.00M 29.00M 36.00M 25.00M
Net income 1091.00M 966.00M 279.00M 191.00M 259.00M
Selling general administrative 2071.00M 1964.00M 1789.00M 1734.00M 1716.00M
Gross profit 5028.00M 4641.00M 3859.00M 3788.00M 3666.00M
Reconciled depreciation 1130.00M 1264.00M 1287.00M 1202.00M 1141.00M
Ebit 1799.00M 1393.00M 731.00M 777.00M 812.00M
Ebitda 2937.00M 2813.00M 2141.00M 2100.00M 1953.00M
Depreciation and amortization 1138.00M 1420.00M 1410.00M 1323.00M 1141.00M
Non operating income net other -32.00M 116.00M 65.00M 13.00M 16.00M
Operating income 1799.00M 1393.00M 731.00M 777.00M 741.00M
Other operating expenses 12583.00M 12461.00M 10576.00M 10236.00M 9603.00M
Interest expense 416.00M 375.00M 416.00M 447.00M 414.00M
Tax provision 260.00M 163.00M 72.00M 116.00M 59.00M
Interest income 403.00M 6.00M 6.00M 9.00M 8.00M
Net interest income -403.00M -369.00M -410.00M -438.00M -406.00M
Extraordinary items - - - 0.00M 35.00M
Non recurring 28.00M 20.00M 52.00M 75.00M 68.00M
Income tax expense 260.00M 163.00M 72.00M 116.00M 59.00M
Total revenue 14410.00M 13874.00M 11359.00M 11088.00M 10412.00M
Total operating expenses 3201.00M 3228.00M 3076.00M 2936.00M 2857.00M
Cost of revenue 9382.00M 9233.00M 7500.00M 7300.00M 6746.00M
Total other income expense net -436.00M -265.00M -358.00M -425.00M -75.00M
Net income from continuing ops 1091.00M 971.00M 301.00M 236.00M 269.00M
Net income applicable to common shares 1091.00M 966.00M 279.00M 191.00M 259.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 25337.00M 24689.00M 24564.00M 23251.00M 22549.00M
Intangible assets 4820.00M 4943.00M 5205.00M 5514.00M 5951.00M
Other current assets 561.00M 521.00M 563.00M 451.00M 322.00M
Total liab 19572.00M 18647.00M 18284.00M 16988.00M 15595.00M
Total stockholder equity 5765.00M 6042.00M 6001.00M 6003.00M 6714.00M
Deferred long term liab 464.00M 410.00M 338.00M 646.00M 736.00M
Other current liab 313.00M 344.00M 344.00M 319.00M 1990.00M
Common stock 10898.00M 10777.00M 11095.00M 11049.00M 10901.00M
Capital stock 10898.00M 10777.00M 11095.00M 11049.00M 10901.00M
Retained earnings 3334.00M 2243.00M 1277.00M 998.00M 807.00M
Other liab 911.00M 1059.00M 971.00M 1072.00M 1140.00M
Good will 13921.00M 13301.00M 12654.00M 12159.00M 11800.00M
Other assets 590.00M 615.00M 1133.00M 346.00M 344.00M
Cash 1216.00M 1366.00M 1814.00M 837.00M 891.00M
Cash and equivalents 1216.00M 1366.00M 1814.00M 837.00M 891.00M
Total current liabilities 5578.00M 5241.00M 4558.00M 3945.00M 3534.00M
Current deferred revenue 1797.00M 1825.00M 1252.00M 1014.00M 1007.00M
Net debt 11795.00M 11072.00M 11090.00M 11204.00M 10116.00M
Short term debt 152.00M 91.00M 149.00M 100.00M 100.00M
Short long term debt 152.00M 91.00M 149.00M 100.00M 100.00M
Short long term debt total 13011.00M 12438.00M 12904.00M 12041.00M 11007.00M
Other stockholder equity -7740.00M -6572.00M -6166.00M -5733.00M -4770.00M
Property plant equipment 863.00M 903.00M 482.00M 458.00M 434.00M
Total current assets 4981.00M 4763.00M 5090.00M 4126.00M 3874.00M
Long term investments 162.00M 164.00M 84.00M 87.00M 142.00M
Net tangible assets -12976.00M -12202.00M -11858.00M -11670.00M -11037.00M
Short term investments 93.00M 111.00M 88.00M 62.00M 47.00M
Net receivables 2960.00M 2609.00M 2466.00M 2638.00M 2463.00M
Long term debt 12595.00M 12034.00M 12384.00M 11545.00M 10907.00M
Inventory 151.00M 156.00M 159.00M 138.00M 151.00M
Accounts payable 3316.00M 2981.00M 2813.00M 2512.00M 437.00M
Noncontrolling interest in consolidated entity - - 279.00M 260.00M 240.00M
Accumulated other comprehensive income -727.00M -406.00M -205.00M -311.00M -224.00M
Common stock total equity 10898.00M 10777.00M 11095.00M 11049.00M 10901.00M
Retained earnings total equity 3334.00M 2243.00M 1277.00M 998.00M 807.00M
Treasury stock - -6572.00M -6166.00M -5733.00M -4770.00M
Non currrent assets other 472.00M 491.00M 386.00M 227.00M 239.00M
Deferred long term asset charges - - - 119.00M 109.00M
Non current assets total 20356.00M 19926.00M 19474.00M 19125.00M 18675.00M
Capital lease obligations 264.00M 313.00M 371.00M 396.00M -
Long term debt total 12595.00M 12034.00M 12384.00M 11545.00M 10907.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2006.00M -10.00M -2.00M -22.00M -23.00M
Change to liabilities 299.00M 835.00M 170.00M 235.00M 250.00M
Total cashflows from investing activities -2006.00M -2103.00M -796.00M -1190.00M -810.00M
Net borrowings 936.00M 70.00M 309.00M 700.00M 993.00M
Total cash from financing activities -329.00M -1235.00M -217.00M -276.00M -452.00M
Change to operating activities 7.00M -15.00M -146.00M -92.00M -66.00M
Net income 1091.00M 971.00M 308.00M 227.00M 284.00M
Change in cash -150.00M -448.00M 977.00M -54.00M -68.00M
Begin period cash flow 1366.00M 1814.00M 837.00M 891.00M 959.00M
End period cash flow 1216.00M 1366.00M 1814.00M 837.00M 891.00M
Total cash from operating activities 2260.00M 2942.00M 1959.00M 1417.00M 1254.00M
Issuance of capital stock - - - - 15.00M
Depreciation 1130.00M 1264.00M 1287.00M 1202.00M 1141.00M
Other cashflows from investing activities -1332.00M 5.00M -178.00M -586.00M -328.00M
Dividends paid - - 13.00M 18.00M 4076.00M
Change to inventory - -17.00M -229.00M -116.00M -184.00M
Change to account receivables -421.00M -138.00M 255.00M -124.00M -297.00M
Sale purchase of stock -1168.00M -406.00M -447.00M -949.00M -1405.00M
Other cashflows from financing activities 3498.00M 1862.00M 2729.00M 4348.00M 8075.00M
Change to netincome 108.00M 15.00M -113.00M -44.00M -76.00M
Capital expenditures 674.00M 640.00M 616.00M 582.00M 459.00M
Change receivables -421.00M -138.00M 255.00M -122.00M -297.00M
Cash flows other operating 38.00M 576.00M 34.00M -94.00M -59.00M
Exchange rate changes - - - - -60.00M
Cash and cash equivalents changes -75.00M -396.00M 946.00M -49.00M -68.00M
Change in working capital -84.00M 680.00M 459.00M 19.00M -106.00M
Stock based compensation 194.00M 170.00M 95.00M 146.00M 113.00M
Other non cash items 44.00M -5.00M -14.00M -20.00M -1.00M
Free cash flow 1586.00M 2302.00M 1343.00M 835.00M 795.00M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IQV
IQVIA Holdings Inc		 6.41
2.36%		 278.24 37.82 19.68 2.76 7.20 3.61 17.03
TMO
Thermo Fisher Scientific Inc		 12.74
1.83%		 707.50 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.52
1.53%		 233.77 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -0.93
3.65%		 24.52 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 1.01
4.03%		 26.02 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.

4820 Emperor boulevard, Durham, NC, United States, 27703

919 998 2000

https://www.iqvia.com

87000

Name Title Year Born
Ms. Keriann Cherofsky Sr. VP, Corp. Controller & Principal Accounting Officer 1984
Mr. Ari Bousbib Chairman, Pres & CEO 1961
Mr. Ronald E. Bruehlman Exec. VP & CFO 1961
Mr. Eric M. Sherbet Exec. VP, Gen. Counsel & Sec. 1964
Mr. Kevin C. Knightly Pres of Corp. Strategy & Enterprise Networks 1961
Dr. Jeffrey A. Spaeder Sr. VP, Global Chief Medical & Scientific Officer NA
Mr. Karl Guenault Sr. VP & Chief Information Officer NA
Andrew Markwick Sr. VP of Investor Relations NA
Mr. Nicholas Childs Sr. VP, Investor Relations & Corp. Communications NA
Ms. Trudy Stein Chief HR Officer & Exec. VP NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +4.21%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.63%

  • Healthcare

    +1.49%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…